| Literature DB >> 30723799 |
Muhammad Amir Khan1, John D Walley2, Nida Khan3, Muhammad Ahmar Khan4, Saima Ali4, Rebecca King5, Shaheer Ellahi Khan6, Faisal Imtiaz Sheikh4, Farooq Manzoor7, Haroon Jehangir Khan8.
Abstract
BACKGROUND: In Pakistan about 18% of all adults are affected by hypertension, and only one in eight of the prevalent cases have their hypertension controlled. As in many other low-middle income countries, a public-private partnership approach is being considered for delivering non-communicable disease care in urban areas. AIM: This process evaluation was undertaken to understand how an integrated care intervention was experienced by the care providers and patients, and to inform modifications before possible scaling. DESIGN &Entities:
Keywords: Integrated care package; general practice; hypertension; mixed methods research; primary health care; private clinics
Year: 2018 PMID: 30723799 PMCID: PMC6348318 DOI: 10.3399/bjgpopen18X101613
Source DB: PubMed Journal: BJGP Open ISSN: 2398-3795
Selected care tasks and key indicators
| Care task | Key indicators | |
|---|---|---|
| Quantitative | Qualitative | |
| Private clinic engagement | 1. Number and/or percentage joined or attended training or withdrew from partnership | District: selects and engages clinics treat a lifelong condition cope: adjusting consultation or drug fees, or operations for dispensing free of cost drugs (provided though the project) |
| Patient identification and examination for diagnosis | 3. Number and/or percentage examined for baseline clinical and laboratory; also age and/or anthropometric measures | Patient’s experiences and provider’s experiences (also practice deviations and reasons) for: identifying and examining overweight and hypertension symptomatic patients conducting clinical and laboratory examinations; and diagnose |
| Treatment | 4. Number and/or percentage of prescribed as per programme guidelines: without comorbid condition with comorbid condition (such as diabetes, renal insufficiency, pregnancy) | Patient’s experiences and provider’s experiences (also practice deviations and reasons) with regards to: prescribing (as per guide) lifestyle trial before drugs prescribing preventive drugs |
| Lifestyle modification | 7. Recording of smoking status (and staff response) | Patient’s experiences of and provider’s experiences (also practice deviation and reasons) for: patient counselling (with pictorial tool) for lifestyle change and smoking cessation |
| Patient follow-up and adherence | 8. Number and/or percentage adhere to follow-up visits (in first 9 months) | Patient’s and provider’s experiences (also practice deviations and reasons) for: patient adherence to follow-up visits (include retrieval) staff adhere to care during follow-up visit referrals (for example,side effects) |
Logic model for the intervention
| Intervention inputs | Intervention process and actions | Intended | ||
|---|---|---|---|---|
| Practice change | Outputs | Health outcome | ||
|
Case management desk guide and lifestyle counselling tool Training of doctors and allied staff (on full care package) Supplement drugs, equipment and supplies (digital BP apparatus, (glucometer and strips)a Recording formsa |
Screen/ diagnosea Prescribe antihypertensive Identify comorbid condition and treat Counsel for lifestyle modification Follow-up care, including retrieval | Providers practice programme protocols to: Screen, diagnose, treat, counsel, follow-up and report as per programme protocol Follow-up visits Treatment Lifestyle changes (as counselled) | Patients get: Screened and diagnosed as per programme protocol Prescribed right drug and/or dose Counselled for lifestyle change Followed-up and treated for continued care |
Reduction (≥10 mmHg) in mean systolic blood pressure |
aInputs and/or practices kept same in intervention and control arms.
Figure 1.Sampling for staff and patient interviews. SBP = systolic blood pressure.
Prescription of antihypertension medication
| Arm | No known comorbid diabetes or proteinuria ( | Known comorbid diabetes and/or proteinuria ( | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Thiazide | ACEi/CCB | Others | ACEi/ARB | Others | ||||||
|
| % |
| % |
| % |
| % |
| % | |
| Intervention | 143 | 37.5 | 214 | 56.0 | 25 | 6.5 | 101 | 52.6 | 91 | 47.4 |
| Control | 56 | 15.0 | 252 | 67.4 | 66 | 17.6 | 92 | 48.4 | 98 | 51.6 |
| Total | 199 | 26.3 | 466 | 61.6 | 91 | 12.1 | 193 | 50.5 | 189 | 49.5 |
ACEi = acetyl cholinestrase inhibitors. ARB = acetyl cholinestrase receptor blockers.CCB = calcium channel blockers.
Prescription of preventive medication among patients with comorbid diabetes and/or hypertension
| Arm | Eligible (comorbid diabetes and/or proteinuria) | Treated | ||
|---|---|---|---|---|
|
|
|
|
| |
| Intervention ( | 192 | 33.4 | 114 | 59.4 |
| Control ( | 190 | 33.7 | 43 | 22.6 |
| Total ( | 382 | 33.6 | 157 | 41 |
Figure 2.Patient attrition in intervention and control arms.